Literature DB >> 17006069

Risk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure.

Jordi Rello1, Camilla Allegri, Alejandro Rodriguez, Loreto Vidaur, Gonzalo Sirgo, Frederic Gomez, Kemal Agbaht, Angel Pobo, Emili Diaz.   

Abstract

BACKGROUND: To facilitate the decision-making process for therapy and prevention of ventilator-associated pneumonia (VAP) in patients undergoing recent antibiotic exposure, this study investigated whether the development of VAP episodes caused by Pseudomonas aeruginosa or other pathogens are related to different risk factors, thereby distinguishing two risk population for this serious complication.
METHODS: A 5-year retrospective case-control observational study was conducted. Cases of VAP caused by P. aeruginosa were compared with those caused by other pathogens. Univariate and multivariate analysis was performed using SPSS 11.0 software (SPSS Inc., Chicago, IL).
RESULTS: Two groups were identified: P. aeruginosa (group P) was isolated in 58 (63.7%) episodes, and 33 episodes served as controls (group C), after a median of 12 days (interquartile range, 4-28 days) and 9 days (interquartile range, 3-12.5 days) of mechanical ventilation, respectively. P. aeruginosa was identified in 34.7% of episodes with early-onset pneumonia and in 73.5% with late-onset pneumonia. In a logistic regression analysis, P. aeruginosa was independently associated with duration of stay of 5 days or longer (relative risk = 3.59; 95% confidence interval, 1.04-12.35) and absence of coma (relative risk = 8.36; 95% confidence interval, 2.68-26.09). Risk for pathogens different from P. aeruginosa (group C) in early-onset pneumonia associated with coma was estimated to be 87.5%.
CONCLUSIONS: Risk factors in episodes under recent antibiotic treatment caused by P. aeruginosa or other microorganism are not the same, a fact that could have implications for preventive and therapeutic approaches for this infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006069     DOI: 10.1097/00000542-200610000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

1.  Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century.

Authors:  Jordi Rello; Bárbara Borgatta; Thiago Lisboa
Journal:  Intensive Care Med       Date:  2013-10-22       Impact factor: 17.440

2.  Non-adherence to guidelines: an avoidable cause of failure of empirical antimicrobial therapy in the presence of difficult-to-treat bacteria.

Authors:  Frédéric Garcin; Marc Leone; François Antonini; Aude Charvet; Jacques Albanèse; Claude Martin
Journal:  Intensive Care Med       Date:  2009-09-24       Impact factor: 17.440

3.  Reduction of Endotracheal Tube Biofilms Using Antimicrobial Photodynamic Therapy.

Authors:  Merrill A Biel; Chet Sievert; Marina Usacheva; Matthew Teichert; Eric Wedell; Nicolas Loebel; Andreas Rose; Ron Zimmermann
Journal:  Lasers Surg Med       Date:  2011-09-01       Impact factor: 4.025

4.  PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice.

Authors:  Arnaud Goolaerts; Mathieu Lafargue; Yuanlin Song; Byron Miyazawa; Mehrdad Arjomandi; Michel Carlès; Jérémie Roux; Marybeth Howard; Dale A Parks; Karen E Iles; Jean-François Pittet
Journal:  Thorax       Date:  2011-07-18       Impact factor: 9.139

5.  Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice.

Authors:  Nastasha Bir; Mathieu Lafargue; Marybeth Howard; Arnaud Goolaerts; Jeremie Roux; Michel Carles; Mitchell J Cohen; Karen E Iles; José A Fernández; John H Griffin; Jean-Francois Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-21       Impact factor: 6.914

6.  α-Tocopherol Attenuates the Severity of Pseudomonas aeruginosa-induced Pneumonia.

Authors:  Brant M Wagener; Naseem Anjum; Cilina Evans; Angela Brandon; Jaideep Honavar; Judy Creighton; Maret G Traber; Robert L Stuart; Troy Stevens; Jean-Francois Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

7.  Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients.

Authors:  Mario Tumbarello; Gennaro De Pascale; Enrico Maria Trecarichi; Teresa Spanu; Federica Antonicelli; Riccardo Maviglia; Mariano Alberto Pennisi; Giuseppe Bello; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2013-02-01       Impact factor: 17.440

8.  The Effect of Listening to Holy Quran Recitation on Weaning Patients Receiving Mechanical Ventilation in the Intensive Care Unit: A Pilot Study.

Authors:  Mohammad Yadak; Khalid Aziz Ansari; Hatem Qutub; Hajed Al-Otaibi; Omar Al-Omar; Nawal Al-Onizi; Faraz Ahmed Farooqi
Journal:  J Relig Health       Date:  2019-02

9.  Efficacy of endotracheal tube suctioning in intubated intensive care unit patients determined by in vivo catheter-based optical coherence tomography-a pilot study.

Authors:  Roshan Dsouza; Darold R Spillman; Ronit Barkalifa; Guillermo L Monroy; Eric J Chaney; Mark A Johnson; Karen C White; Stephen A Boppart
Journal:  Quant Imaging Med Surg       Date:  2021-01

10.  Occurrence of aminoglycoside-modifying enzymes genes (aac(6')-I and ant(2″)-I) in clinical isolates of Pseudomonas aeruginosa from Southwest Nigeria.

Authors:  Bamidele Tolulope Odumosu; Bolanle A Adeniyi; Ram Chandra
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.